BioNTech and Pfizer request authorization from the EMA to vaccinate adolescents

The pharmaceutical companies BioNTech and Pfizer have asked the European Medicines Agency (EMA) to extend the authorization of their coronavirus vaccine to adolescents between 12 and 15 years old , both companies reported today.

In a joint statement, they explain that they tested their formula against the coronavirus in 2,260 adolescents in phase three and that, as they announced at the end of March, the effectiveness of the vaccine was 100% and with a “solid” immune response.

The German BioNTech and the American Pfizer also indicate that they have already taken a similar step in the United States , where they have requested that their current emergency permit be adapted, and that they plan to request the same in other districts.